Australia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
40.02+0.48 (+1.21%)
At close: 04:00PM EST
39.30 -0.72 (-1.80%)
After hours: 07:14PM EST
Full screen
Trade prices are not sourced from all markets
Previous close39.54
Open37.94
Bid39.26 x 900
Ask39.99 x 3100
Day's range37.65 - 41.08
52-week range14.48 - 146.16
Volume1,084,800
Avg. volume4,726,138
Market cap1.601B
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target estN/A
  • Zacks

    Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

    Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

  • Motley Fool

    Where Will Cassava Sciences Be in 1 Year?

    First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.

  • Motley Fool

    3 Healthcare Stocks That Could Rocket Higher in 2022

    A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.